

ASX ANNOUNCEMENT

16 May 2018

DOTZ ACHIEVES IPO PERFORMANCE MILESTONE

Dotz Nano Limited (ASX: DTZ) ("Dotz Nano" or the **"Company"**), is pleased to advise that it has achieved one of its key performance milestones (Milestone A). Milestone A specified the production and distribution of an aggregate of 20 kilograms of GQDs through formal off-take agreements or commercial samples with reputable third parties.

Milestone A was required to be achieved within an 18-month period from the date of issue of the Performance Shares on ~15 November 2016.

66,000,000 Consideration Shares and 66,000,000 Performances Shares were issued to the shareholders of Datz Nano Limited (Israel) as part of the merger of the Company and Dotz Nano Limited (Israel) before the Company's IPO.

The Company advises that Milestone A has been achieved and that 22,000,000 Performance Shares have been converted into 22,000,000 ordinary fully paid shares (Shares).

The attached Appendix 3B includes full details of the Performance Rights converted to Ordinary Shares

A further 44,000,000 Performance Shares will convert upon satisfaction of any one of the following milestones:

- Milestone B 22,000,000 Performance shares shall convert upon Dotz achieving the production and distribution of an aggregate of 50 kilograms of GQDs in any 12-month period through formal off-take agreements with a reputable third party within a period of 30 months from the issue date; and
- Milestone C 22,000,000 Performance shares shall convert upon Dotz achieving the production
 and distribution of an aggregate of 100 kilograms of GQDs in any 12-month period through formal
 off-take agreements with a reputable third party within a period of 48 months from the issue date.

FOR FURTHER INFORMATION:

Company Secretary
Ian Pamensky
ian@cfo2grow.com.au
+61 (0) 414 864 746

About Dotz Nano

Dotz Nano Limited (ASX: DTZ) is a technology company focusing on the development, manufacture and commercialisation of GQD/CDs. Its vision is to be the premier producer of GQD/CDs by producing and supplying high quality GQD/CDs for use in various applications including medical imaging, sensing, consumer electronics, energy storage, solar cells and computer storage.

To learn more about Dotz Nano please view the website and our corporate video via the following link: www.dotznano.com

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

01/08/12, 04/03/13			
Name of	fentity		
Dotz N	ano Limited		
ABN			
	5 264 575		
We (th	e entity) give ASX the following in	nformation.	
Part	1 - All issues		
You mus	st complete the relevant sections (attach s	heets if there is not enough space).	
1	*Class of *securities issued or to	1. Fully paid ordinary shares	
	be issued	2. Fully paid ordinary shares	
า	N 1 C+	1 2044024	
2	Number of *securities issued or to be issued (if known) or	1. 2,044,034 2. 19,955,966	
	maximum number which may be issued		
	155404		
3	Principal terms of the *securities	Fully paid ordinary shares	
	(e.g. if options, exercise price and expiry date; if partly paid	2. Fully paid ordinary shares escrowed 24 months from quotation	
	+securities, the amount	months from quotation	
	outstanding and due dates for payment; if *convertible		
	securities, the conversion price		
	and dates for conversion)		

⁺ See chapter 19 for defined terms.

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

- 1. Yes the fully paid ordinary shares will rank equally with existing quoted fully paid ordinary shares
- 2. Yes the fully paid ordinary shares will rank equally with existing quoted fully paid ordinary shares

- 1. \$nil
- 2. \$nil
- 1. Achievement one of its key performance milestones (Milestone A). Milestone A specified the production and distribution of an aggregate of 20 kilograms of GQDs through formal off-take agreements or commercial samples with reputable third parties within an 18-month period from the date of issue of the Performance Shares on ~15 November 2016
- 2. Achievement one of its key performance milestones (Milestone A). Milestone A specified the production and distribution of an aggregate of 20 kilograms of GQDs through formal off-take agreements or commercial samples with reputable third parties within an 18-month period from the date of issue of the Performance Shares on ~15 November 2016.
- 6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

N/A

N/A

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6c	Number of *securities issued without security holder approval under rule 7.1	 2,044,034 Ordinary Shares 19,955,966 Fully paid ordinary shares escrowed 24 months from quotation
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of *securities issued under an exception in rule 7.2	Nil
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
		<u> </u>
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 15,866,279 7.1A 14,409,591
7	+Inque datas	15 May 2010
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	15 May 2018

⁺ See chapter 19 for defined terms.

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	⁺ Class
90,938,183	Fully paid ordinary shares

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class	
80,905,838	Fully paid ordinary	
	shares escrowed 24 months from quotation	
39,911,932	Performance shares escrowed 24 months from quotation	
4,088,068	Performance shares	
4,500,000	Options expiring 31/10/19, exercise price \$0.40 each, escrowed 24 months from quotation	
1,000,000	Options expiring 31/10/19, exercise price \$0.30 each, escrowed 24 months from quotation	
5,000,000	Options expiring 14/6/20 2020, exercise price \$0.20 each, escrowed 24 months from quotation	
10,000,000	Options expiring 8/8/19, exercise price \$0.20	
6,000,000	Options expiring 5/2/20, exercise price \$0.30	
1,000,000	Options expiring 1/11/20, exercise price \$Nil	
1,000,000	Options expiring 20/04/20, exercise price \$Nil	
212,500	Options expiring 20/04/20, exercise price \$0.105.	
212,500	Options expiring 20/04/20, exercise price \$0.105. Vesting after 1 February 2019	
1,000,000	Options expiring 20/04/20, exercise price \$0.20.	

⁺ See chapter 19 for defined terms.

Dividend policy (in the case of a N/A trust, distribution policy) on the increased capital (interests)

Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the ⁺ securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
20	5	
28	Date rights trading will begin (if applicable)	
20	D	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

⁺ See chapter 19 for defined terms.

32	Ном	do cocurity holders dispose	
32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	
33	+Issue	e date	
		uotation of securition	
34	Type (tick o	of ⁺ securities one)	
(a)		⁺ Securities described in Part	1
(b)		All other ⁺ securities	
			nd of the escrowed period, partly paid securities that become fully paid, n restriction ends, securities issued on expiry or conversion of convertible
Entitie	es tha	t have ticked box 34(a)	
Additi	onal s	ecurities forming a new cl	ass of securities
Tick to docume		e you are providing the informati	on or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			securities, a distribution schedule of the additional mber of holders in the categories
		1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for t	ha additional †securities
37		n copy of any trust uccu for t	ne additional securities

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Entitie	s that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other +security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 †securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 16 May 2018

Print name: **Ian Pamensky**.....

(Company secretary)

== == == == ==

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	109,984,802	
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2		
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval	12,500,000 approved at shareholder meeting held on 5/10/2017 21,611,111 approved at shareholder meeting held on 16/01/2018	
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period		
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-	
"A"	144,095,913	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	21,614,387	
Step 3: Calculate "C", the amount of placement capacity under rul 7.1 that has already been used		
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	363,108 – Placement – 10/05/2018 5,385,000 – Issue – 10/05/2018	
Under an exception in rule 7.2		
 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 		
Note: • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items		
"C"	5,748,108	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1		
"A" x 0.15	21,614,387	
Note: number must be same as shown in Step 2		
Subtract "C"	5,748,108	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	15,866,279	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1	144,095,913	
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	14,409,591	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items		
	-	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	14,409,591	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	14,409,591	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.